Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTATOC + capecitabine + temozolomide
- Development stage
- Unknown
- Lead developer
- University of Warmia and Mazury
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous, Oral
01
Overview
177Lu-DOTATOC + capecitabine + temozolomide is an investigational combination therapy regimen being evaluated for the treatment of advanced, non-resectable, and progressive gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). The regimen utilizes **177Lu-DOTATOC** (lutetium (177Lu) edotreotide), a radiopharmaceutical consisting of the beta-emitting radioisotope Lutetium-177 chelated to the somatostatin analog DOTATOC. This component targets somatostatin receptors (primarily SSTR2) overexpressed on tumor cells, delivering targeted ionizing radiation. The chemotherapy components, **capecitabine** and **temozolomide** (collectively known as CAPTEM), are administered to provide additional cytotoxic effects and act as radiosensitizers to enhance the efficacy of the peptide receptor radionuclide therapy (PRRT). This specific therapeutic approach is currently under investigation in a Phase II clinical trial led by the University of Warmia and Mazury.
- Other names
- 177Lu-DOTATOC + CAPTEM177Lu-edotreotide + capecitabine + temozolomide
02
Targets
SSTR2 (Somatostatin receptor type 2)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on 177Lu-DOTATOC + capecitabine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTATOC + capecitabine + temozolomide.